

MANAGEMENT
DISCUSSION
AND ANALYSIS

FY 2025

Table of Contents

01 <u>CEO Message & FY 2025 Key Highlights</u>	06 <u>Cash Flow Analysis</u>
02 <u>Overview</u>	07 <u>Balance Sheet Analysis</u>
03 <u>Operational Highlights</u>	08 <u>Guidance</u>
04 <u>Group Income Statement Analysis</u>	09 <u>Capacity Enhancements & Achievements</u>
05 <u>Detailed Segment Performance</u>	10 <u>Appendix</u>



CEO Message



PureHealth delivered a strong performance in 2025, reflecting sustained growth across both our Care and Cover segments and the resilience of our integrated platform. Disciplined execution, growth in patient volumes, strong insurance renewal rates, and increased diagnostic activity supported by continued operational excellence.

Throughout the year, we made meaningful progress in driving strategic growth through transformation, selectively expanding higher-value specialty services, advanced diagnostics and targeted international investments aligned with our long-term vision. The successful acquisition of Hellenic Healthcare Group (HHG), alongside synergies realisation with Circle, reinforced our ability to scale, integrate, and extract value across the platform while building a globally connected, innovation-led healthcare ecosystem.

Operational efficiency, profitability, and cash generation improved meaningfully supported by a strong balance sheet and a disciplined capital allocation framework. This enabled continued investment in priority digital capabilities, including electronic health records, workforce optimisation platforms, and AI-driven analytics to enhance care quality, standardisation, and scalability.

Looking ahead, we remain focused on sustainable growth through operational efficiencies, technology enablement, and targeted acquisitions, while deepening platform integration to deliver long-term value for patients, partners, and shareholders.

Key Highlights of FY 2025

Revenue	AED 27.3 Bn	▲ +6% YoY	Patient Interactions*	11.0 Mn
EBITDA	AED 4.8 Bn	▲ +16% YoY		+16% YoY
EBITDA Margin	17.5%	▲ +1.6 ppts YoY	Operational Beds*	6.9 K
Net Profit	AED 2.0 Bn	▲ +18% YoY		+27% YoY
EPS	AED 0.18	▲ +17% YoY	Inpatient Volume*	250 K
Total Assets	AED 57.2 Bn	▲ +18% vs FY24		+22% YoY
			Outpatient Volume*	9.7 Mn
				+17% YoY
			UAE Test Volumes	34.0 Mn
				+17% YoY
			GWP	AED 7.6Bn
				+9% YoY

* Figures Include UAE, UK, Cyprus and Greece operations

Overview

Abu Dhabi, February 2026 – PureHealth, the UAE's largest healthcare group with expanding global operations, reported strong financial results for 2025. Strategic investments in capacity expansion, service diversification, and physician recruitment drove higher patient volumes across our facilities. This expanded patient base continues to fuel momentum and growth across PureHealth's integrated healthcare platform.

PureHealth operates through two strategic verticals - **Care** (Healthcare) and **Cover** (Insurance) - each designed to deliver world-class healthcare services and insurance solutions.

The Care Vertical, which includes the Hospitals, Diagnostics, Procurement, and Technology segments, encompasses a comprehensive ecosystem of medical service providers, including the UAE's largest healthcare group with 24 hospitals and approximately 5,000 licensed beds, and Circle Health, the UK's largest private healthcare group, which operates over 50 hospitals with 2,000+ licensed beds. As of October 2025, PureHealth completed the acquisition of 60% stake in Hellenic Healthcare Group (HHG), Greece and Cyprus's leading private healthcare provider, strengthening its global platform. HHG financials were consolidated from 1st of October 2025.

The Cover Vertical is represented by Daman, one of the UAE's leading insurers. Its Health Insurance segment provides coverage to 3.4 million members and processes more than 56 million claims annually. Daman is also expanding into Property & Casualty insurance, evolving into a diversified insurance powerhouse with a widening footprint.

In 2025, PureHealth delivered robust financial results supported by broad-based growth across our segments:

- **Revenue** increased 5.7% YoY to AED 27.3 billion, driven by strong topline growth across both the Cover and Care segments. Performance in Q4 2025 was supported by the contribution from Hellenic Healthcare Group, which added AED 742 million to Group revenue.
- **EBITDA** grew 16.1% YoY to AED 4.8 billion, with the EBITDA Margin expanding by 1.6 ppts to 17.5%, reflecting strong operational excellence and disciplined cost management across both the Care and Cover segments. Q4 2025 performance was further supported by Hellenic Healthcare Group, which contributed AED 152 million to EBITDA at a strong margin of 20.5%, enhancing overall profitability.
- **Net Income** rose 17.7% YoY to AED 2.0 billion, with the net income margin improving to 7.4%. This growth was achieved despite non-operational items¹ and a higher tax rate of 15%, compared to 9% last year, following the implementation of Pillar Two tax requirements, highlighting exceptional performance within the Cover segment and enhanced operational efficiencies in the Care segment.

PureHealth's performance underscores the Group's disciplined execution and operational resilience amid ongoing expansion efforts. With a strong balance sheet, an expanding international footprint, and sustained investment in growth, the company remains well positioned to achieve its medium-term strategic and financial targets.

¹ Share of profit in Ardent was reclassified from being an associate to an investment at fair value post its listing in July 2024. Also, the current period includes the PPA intangibles, Yas Clinic Group / ADSCC was divested at the beginning of Q2 224

FY 2025 Operational Highlights

PureHealth maintained strong strategic momentum during the year, driving growth through landmark partnerships, targeted acquisitions, tech-enablement and operational efficiencies. The Group continued to enhance its healthcare ecosystem by expanding inpatient and outpatient capacity through new specialty clinics, advancing diagnostic capabilities, and strengthening surgical care services, all supported by the recruitment of top-tier medical professionals. These initiatives reinforce PureHealth's commitment to delivering exceptional, best-in-class healthcare services across an expanding footprint. Key developments across our Care and Cover verticals include:

UAE Care

SEHA, SEHA Clinics and SSMC



Expansion of Advanced Specialized and Complex Care Services

SEHA further strengthened its position as the UAE's leading healthcare network through the **continued expansion of advanced specialized and complex care services**. During the year, SEHA launched its **liver transplant program**, adding one of the highest-acuity surgical capabilities to the network, completing **33 liver transplants**. This was complemented by continued growth in transplant nephrology, with **130 kidney transplants performed** in 2025 and 794 transplants completed to date, reinforcing SEHA's role as a regional leader in complex organ care.

SEHA also introduced advanced capabilities and achieved significant breakthrough by becoming the **first in the world to deliver ITVISMA™ gene-replacement therapy** for the treatment of **spinal muscular atrophy (SMA)**. This next-generation therapy replaces the missing SMN1 gene to improve motor function and reduce long-term treatment burden, marking a significant step forward in personalized and precision medicine within the UAE.

Critical care capabilities were further enhanced through the **introduction of ER ECPR (Emergency Room Extracorporeal Cardiopulmonary Resuscitation) and the expansion of ECMO services**, elevating SEHA's emergency and critical care capacity and improving survival outcomes for patients experiencing the most severe cardiac and respiratory emergencies.

Specialized cardiac care also advanced with the **introduction of adult Cardiothoracic surgery and advanced cardiac services in Al Ain**, establishing Al Ain region's only dedicated cardiothoracic program.

Development of Specialized Centers & Advanced Care Capabilities

SSMC strengthened its position as a regional leader in advanced and high-acuity care by expanding complex care capabilities across key specialties. Major advancements included the launch of an **advanced Electrophysiology (EP) lab**, enabling state-of-the-art cardiac interventions, and several **first-in-Abu Dhabi clinical interventions**, such as the Auditory Brainstem Implant, for patients with absent cochlear nerve and the Hypoglossal Nerve Implant for sleep apnea. These developments have elevated SSMC's clinical sophistication and reinforced its role as a referral destination for complex, high-value care.

To meet growing demand for specialized paediatric neurological services, **SSMC opened a dedicated Paediatric Epilepsy Monitoring Unit** during the year, enhancing early diagnostic accuracy and enabling comprehensive evaluation of complex epilepsy cases.

SSMC advanced its surgical innovation strategy through the deployment of the **Globus Excelsius GPS robotic navigation system**, enabling greater precision, safety, and efficiency in complex spine procedures.

Expanded Patient Care

To support rising demand, SEHA **expanded patient access through extended operating hours, optimized patient scheduling and referral pathways** and the introduction of new specialty services. These efforts were enabled by a significant scale-up of the clinical workforce with more than **350 physicians** added across the network.

Outpatient capacity was further increased through the **opening of six new clinics, including Saadiyat, Masoudi, and Rowda**, alongside the **rollout of additional specialized clinics** within existing facilities such as the Comprehensive Diabetes Care Clinic. Collectively, these expansions enhanced SEHA's reach, accessibility, and ability to deliver high-quality care across the emirate.

Capacity Expansion

Diagnostic imaging capability was further strengthened by **introducing advanced PET scanning services**, enabling earlier and more accurate detection of complex conditions such as oncology, neurology, and infectious diseases. Within just six months of launch, the service completed **771 PET studies**.

Strategic Partnerships

SEHA has entered a landmark strategic partnership with Cincinnati Children's Hospital to deliver world-class paediatric expertise to Abu Dhabi and the UAE. This initiative supports efforts to strengthen local specialised care capacity, reduce reliance on overseas treatment, and reinforce Abu Dhabi's position as a global leader in advanced paediatric medicine and healthcare delivery.

SEHA partnered with Schoen Clinic Group, Germany's leading rehabilitation & mental healthcare provider, to deliver world-class Inpatient & Outpatient rehabilitation services, enhancing SEHA's capabilities and establishing Sheikh Tahnoon Bin Mohammed Medical City (STMC) as a regional Centre of Excellence for rehabilitative care.

SEHA Clinics earned multiple **Gold and Platinum Awards** across key categories at the Arab Hospitals Federation Awards – 2025, including:

- Safety & Quality of Care
- Patient-Centered Care
- Leadership & Governance

Advancing AI, Automation and Operational Excellence

Group-wide optimization & digital transformation were driven through the launch of the AI Factory, enabling scalable and compliant AI deployment across the Group. **A unified Health Information System was rolled** out across PureHealth facilities, while Cyber Security services were successfully expanded to UK and Greece. In addition, more than 100 technological initiatives were delivered in 2025.

Rafed

Rafed continued to demonstrate operational excellence, solidifying its position as a strategic partner in healthcare logistics across the broader national healthcare ecosystem. Rafed was appointed as the **Abu Dhabi Department of Health's Exclusive Distributor for Unified Purchasing Program (UPP)**, a government led procurement initiative.

Rafed also partnered with Abu Dhabi government to create **Regional Vaccine Distribution Hub**, delivering world-class vaccine distribution across the Middle East, Africa, and South Asia.

PureLab



PureLab launched MENA's largest AI-powered standalone diagnostic laboratory. The facility is designed to process more **than 30 million samples annually**, across a comprehensive range of pathology, molecular, and specialised diagnostics.

International Care

Hellenic Healthcare Group



On October 8th, PureHealth completed the acquisition of a 60% stake in Hellenic Healthcare Group (HHG), the leading private healthcare provider in Greece and Cyprus, for c. EUR 800 million. The transaction implies a 100% equity valuation of EUR 1.3 billion and represents a key milestone in PureHealth's strategy to build a globally connected, innovation-driven healthcare platform anchored in Abu Dhabi. **HHG's financials were consolidated from 1st of October 2025.**

The integration of HHG's 11 hospitals and 23 diagnostic centres will expand access to high-quality healthcare for over 1.4 million patients annually. With over 6,500 healthcare professionals, **HHG has become a core part of PureHealth's international ecosystem**, reinforcing Abu Dhabi's position as a global hub for healthcare excellence and investment.

Circle Health Group



Circle Health Group strengthened its clinical footprint through bolt-on acquisitions of **Fairfield Independent Hospital**, adding 28 beds and two operating theatres, and Meriden Hospital Advanced Imaging Centre. Capacity was further expanded through the opening of new outpatient centres in **Cheshire and Inverness**.

Cover

Daman



Daman has expanded strategically into the high-growth **Property and Casualty (P&C) insurance segment** through the **acquisition of a P&C insurance license**. This marks a key step in Daman's evolution from a health-focused insurer to a diversified, **multi-line insurance platform**.

Daman advanced its **digital transformation agenda** with the launch of its first AI-based document intelligence solution, automating the processing of over 60 million documents annually. This has significantly **reduced manual processing**, improved accuracy and shortened turnaround time.

This advanced solution leverages artificial intelligence for intelligent classification, validation, and data extraction. The platform delivers exceptional efficiency gains, faster turnaround times for members and providers, and a stronger foundation for Daman's fully digitized operations.

By embedding AI-driven intelligence at the heart of its operations, Daman is not only enhancing productivity and service quality but also **setting new benchmarks for digital excellence and innovation in the regional insurance sector**.


Group Income Statement Analysis

AED Mn	Q4 2025	Q4 2024 (Reclassified) ²	Δ%	FY 2025	FY 2024 (Reclassified) ²	Δ%
Revenue	7,211	6,892	+5%	27,312	25,848	+6%
Cost of sales	(5,600)	(5,654)	-1%	(20,579)	(19,202)	+7%
Gross profit	1,611	1,238	+30%	6,733	6,646	+1%
G&A expenses, incl. selling & distribution	(1,240)	(1,150)	+8%	(4,732)	(4,735)	-0%
Finance costs	(287)	(243)	+18%	(865)	(848)	+2%
Other operating income	414	404	+2%	1,106	715	+55%
Profit before tax	498	250	+99%	2,242	1,778	+26%
Income tax expense	(28)	30	-196%	(222)	(62)	+258%
Net Profit for the year	470	279	+68%	2,020	1,716	+18%
EBITDA	1,311	993	+32%	4,781	4,119	+16%
Gross Profit Margin	22.3%	18.0%	+4.3ppcts	24.7%	25.7%	-1.0ppcts
EBITDA Margin	18.2%	14.4%	+3.8ppcts	17.5%	15.9%	+1.6ppcts
Net Profit Margin	6.5%	4.1%	+2.4ppcts	7.4%	6.6%	+0.8ppcts

Segment contribution – FY 2025



Total Revenue

EBITDA

Net Profit


²Previously, government grants were recorded entirely as income. However, the impact of these grants has now been reclassified and appropriately reflected in the respective income and expense accounts

+6% YoY ▲

Revenue Growth

+16% YoY ▲

EBITDA Growth

+18% YoY ▲

Net Profit Growth

+22% YoY ▲

Inpatient Footfall

+17% YoY ▲

Outpatient Footfall

+10% YoY ▲

Emergency Dept
Footfall

Group revenue maintained strong momentum in Q4, rounding off a robust FY 2025 performance, driven by strong performance across both the Care and Cover verticals.

The Care segment benefited from higher patient and diagnostics volumes, driven by ongoing capacity and service expansion and Q4 contributions from the integration of HHG.

The Cover segment continued to deliver strong growth, driven by robust policy renewals and new customer acquisitions, reinforcing the Group's continued market momentum.

Group EBITDA increased by 16% YoY to AED 4.8 billion, with the EBITDA margin expanding to 17.5%, reflecting operational efficiency gains and the positive impact of service enhancements across the network. Despite regulatory headwinds in both the UAE and the UK, performance remained robust across the Care and Cover segments.

Net profit increased by 18% YoY to AED 2.0 billion, with the net profit margin improving by 0.8 percentage points to 7.4%, demonstrating sustained profitability, operational discipline, and resilience across PureHealth's diversified portfolio. This performance was achieved despite an increase in the effective corporate tax rate to 15% from 9% following the implementation of Pillar Two framework.

Detailed Segment Performance

Care

AED Mn	Q4 2025	Q4 2024	Δ%	FY 2025	FY 2024	Δ%
Revenue	5,173	5,108	+1%	19,554	19,011	+3%
Total OPEX	(4,912)	(5,004)	-2%	(18,175)	(17,457)	+4%
EBITDA	1,116	896	+25%	3,808	3,474	+10%
EBITDA margin	21.6%	17.5%	+4.1ppts	19.5%	18.3%	+1.2ppts
Profit Before Tax	319	169	+89%	1,330	1,198	+11%
Net Profit	309	204	+52%	1,218	1,190	+2%
Net Profit margin	6.0%	4.0%	+2.0ppts	6.2%	6.3%	-0.1ppts

+3% YoY ▲

Revenue Growth

19.5% ▲

EBITDA Margin

11.0 Mn ▲

Patient Interactions

34.0 Mn ▲

Testing Volumes

Care revenue grew by 3% in FY 2025, driven primarily by higher patient and diagnostics volumes, supported by ongoing capacity expansion, service enhancements across the network, and the Q4 contribution from the integration of HHG.

UAE Care generated AED 12bn of revenue during the year. Excluding the impact of the Unified Purchasing Program (UPP) and internal revenue eliminations, UAE care would have delivered 8% YoY growth, driven by higher patient volumes from capacity expansion, new clinic openings, extended operating hours, and physician additions.

In the UK, Circle delivered 8% revenue growth in FY 2025, underpinned by strong performance across inpatient, day-case, and outpatient services, a higher-acuity case mix, and increased revenue per patient.

HHG demonstrated strong early momentum, with Q4 2025 patient volumes up 7% YoY, driven primarily by outpatient growth in line with HHG's strategic priorities. In Q4, Hellenic Healthcare Group added AED 742 million to Group revenue and contributed AED 152 million to EBITDA.

EBITDA and EBITDA margin improved year-on-year, supported by continued efficiency gains and service enhancements, which helped offset regulatory pressures in both the UAE and the UK; the consolidation of HHG in Q4 provided an incremental uplift to EBITDA growth.

Net profit in FY 2025 was impacted by non-operational items³ and a higher effective tax rate of 15%, compared with 9% last year, following the implementation of Pillar Two tax requirements.

Normalizing for these factors and excluding HHG, **net profit margin expanded by 130 basis points to 7.7%**, up from 6.4% in the prior year.

³ Share of profit in Ardent was reclassified from being an associate to an investment at fair value post its listing in July 2024. Also, the current period includes the PPA intangibles and Yas Clinic Group / ADSCC which was divested at the beginning of Q2'24

Cover

AED Mn	Q4 2025	Q4 2024	Δ%	FY 2025	FY 2024	Δ%
Revenue	2,038	1,785	+14%	7,758	6,838	+13%
Total OPEX	(1,927)	(1,799)	+7%	(7,136)	(6,480)	+10%
EBITDA	195	97	+101%	973	645	+51%
EBITDA margin	9.6%	5.4%	+4.2ppcts	12.5%	9.4%	+3.1ppcts
Profit Before Tax	179	80	+122%	912	579	+57%
Net Profit	161	75	+113%	802	526	+53%
Net Profit margin	7.9%	4.2%	+3.7ppcts	10.3%	7.7%	+2.6ppcts

+13% YoY ▲

Revenue Growth

+9% YoY ▲

GWP Growth

12.5% ▲

EBITDA Margin

3.4 M ▲

Active Members

+43% ▲

Investment Income
Growth

The Insurance segment delivered strong growth in FY 2025, driven by solid renewal activity and continued new-customer acquisition, underscoring sustained market momentum.

Gross written premium (GWP) growth remained strong over the period, supported by high renewal rates and new business acquisition.

Daman's active membership reached 3.4 million, representing a 6% YoY increase, reaffirming customer trust and the enduring strength of its value proposition.

EBITDA and margins expanded in Q4 and across FY 2025, supported by efficiency gains from AI-enabled cost-management initiatives and improved claims-management performance.

Net profit rose 53% YoY, despite the implementation of Pillar Two taxation, supported by resilient customer retention and solid investment income.

In parallel, Daman continued to advance its expansion into the high-growth P&C Insurance segment, marking its transformation into a multi-line insurer.

Balance Sheet Analysis

AED Mn	FY 2025	FY 2024	Δ%
Total Non-Current Assets	37,141	25,844	+44%
Right of use assets	12,671	11,019	+15%
Intangible Assets	12,568	8,644	+45%
Property & equipment	7,397	3,277	+126%
Other non-current assets	4,504	2,904	+55%
Total Current Assets	20,021	22,731	-12%
Trade & other receivables	5,923	4,843	+22%
Cash & Bank Balance	7,706	11,978	-36%
Reinsurance contract assets	1,586	1,527	+4%
Other current Assets	4,806	4,383	+10%
Total Assets	57,162	48,575	+18%
Total Non-Current Liabilities	24,032	16,757	+43%
Lease liabilities	14,475	12,205	+19%
Borrowings	2,834	1,834	+54%
Employee end of service Benefits	1,621	1,506	+8%
Other non-current liabilities	5,103	1,212	+321%
Total Current Liabilities	14,808	12,081	+23%
Trade & other payables	9,294	7,576	+23%
Lease liabilities	501	307	+63%
Contract liability	61	57	+7%
Borrowings	415	26	+1484%
Other current liabilities	4,537	4,115	+10%
Total Liabilities	38,840	28,838	+35%
Total Equity	18,322	19,737	-7%
Total Liabilities & Equity	57,162	48,575	+18%

AED Mn	FY 2025	FY 2024	Δ
Total Bank Debt	3.2	1.9	75%
Bank Debt to Equity	0.2 x	0.1 x	0.1x
Cash & Bank Balance	7,706	11,978	-36%
Net Debt (Incl. lease liabilities adjusted for restricted cash)	11,780	3,595	228%
Total Lease Liabilities	14,976	12,512	20%
Net Debt / EBITDA	2.5x	0.9x	+1.6x

Net Debt Position: The balance sheet remains strong, with a Net Debt to EBITDA ratio of 2.5x. During the year, the Group proactively strengthened its capital structure through the early repayment of AED 1.85 billion of debt originally maturing in 2027. Bank debt stood at AED 3.2 billion at year end, relating entirely to the consolidation of Hellenic Healthcare Group's debt.

Cash Flow Analysis

AED Mn	Q4 2025	Q4 2024	Δ%	FY 2025	FY 2024	Δ%
Net Profit for the period before tax	498	250	+99%	2,242	1,778	+26%
Non-cash Adjustments	945	747	+26%	2,629	2,511	+5%
Working Capital Changes ⁴	1,798	2,643	-32%	(605)	122	-597%
Employees' end of service benefits paid net	(43)	(44)	-2%	(191)	(157)	+22%
Other	36	(813)	-104%	854	(35)	-2562%
Net cash, operating activities	3,235	2,783	+16%	4,929	4,219	+17%
Net cash, investing activities	(4,404)	374	-1277%	(6,250)	(3,645)	+71%
Net cash, financing activities	(304)	(265)	+15%	(3,106)	237	-1412%
Net change in cash & cash equivalents during the period	(1,473)	2,893	-151%	(4,427)	810	-646%
FX rate changes during the period	(3)	(43)	-94%	62	(8)	-844%
Cash & cash equivalents at the beginning of the period	5,900	5,939	-1%	8,789	7,987	+10%
Cash & cash equivalents at the end of the period	4,424	8,789	-50%	4,424	8,789	-50%

Cash Flow from Operations: In 2025, the Group generated AED 4,929 million in **positive cash flow from operations**, compared to AED 4,219 million in 2024, an increase of 17% year-on-year. This strong performance was primarily driven by higher profitability and increased cash inflows from operating activities, supported by the maturity of fixed deposits and the redeployment of capital into higher-yield investment opportunities.

⁴ Working capital does not include reinsurance contract assets/liabilities, other liabilities and restricted cash.

Guidance

Medium-term Financial and Strategic Targets

	FY 2025	Medium-Term Target (2026-2029)
Revenue Growth (vs prior period)	+5.7%	Mid- to High teens (Including M&A)
International Revenue Share ⁵	26.4%	c.50%
Care: EBITDA Margin <small>Medium-term target applicable specifically to Healthcare and in view of continued Group-wide M&A activity</small>	19.5%	Low 20s
CAPEX as % of Revenue	4.0%	<5%
Net Debt ⁶ / EBITDA	2.5x	3.0x
Dividend Payout Ratio	30%	30%

⁵ Share of international business as % of revenue, after intercompany eliminations.

⁶ Incl. lease liabilities, adjusted for restricted cash items.

Capacity Enhancements & Achievements

SEHA & SEHA Clinics



- Launched a Liver Transplant program, adding high-acuity capability with 33 liver transplants in 2025.
- Expanded Transplant Nephrology, performed 130 Kidney transplants in 2025 and 794 to date
- Expanded service time through increase in operating hours across various hospitals and specialties across SEHA.
- Significantly expanded outpatient capacity within UAE through addition of specialized clinics in existing facilities.
- Opened six additional clinics across new geographic areas (Saadiyat, Masoudi, Rowda, etc.)
- Expanded specialty care in the Al Ain region with new Orthopedic Joint reconstruction and Surgical proctology services.
- Established the first Musculoskeletal (MSK) embolization service in the UAE, including genicular artery embolization, embolization for frozen shoulder, and embolization for tennis elbow
- Introduced Advanced PET services in SSMC to cater to complex imaging requirements. 771 studies were performed within six months.

SSMC



- Launched a Paediatric Epilepsy Monitoring Unit (EMU) Clinic as part of the commitment to advancing neurological care, providing specialized services for children with seizure disorders and offering comprehensive diagnostic and treatment capabilities.
- Added in new specialised clinics like
 - Multidisciplinary Memory Clinic
 - Specialised Perimenopause Clinic
 - Women's Mental Health Clinic
 - Barakatna Clinic for Seniors
 - Dedicated Travel Health Clinic
 - Cancer Survivorship Clinic
- Introduced Paediatric Dermatology, a unique offering in the region, to ensure access to expert care
- Launched Transcranial Magnetic Stimulation (TMS), a procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of major depression.
- Expanded Burn Surgery Clinic, new offerings include CO₂ Laser (outpatient and short-stay), Medical Micropigmentation, and Camouflage therapy.
- Introduced Renal Denervation Programme for patients with persistent uncontrolled hypertension using advanced interventional technologies.

Circle Health



- Bolt-On acquisition of Fairfield Independent Hospital, adding 28 beds and two operating theatres
- Bolt-On acquisition of Meriden Hospital Advanced Imaging Centre.
- Opening of the Cheshire Outpatient Clinic in Northwich
- Opening of Inverness Outpatient Clinic in Scotland.
- Expanded cardiology services through the addition of new specialist physicians, enhancing clinical capability and patient care delivery.
- Rollout of Velys robotics across the Group with 18 robots deployed, the largest fleet of Velys across Europe, giving Circle a market edge allowing to attract highly sought-after surgeons.
- Other robots deployed across the group include
 - Da Vinci robots
 - Stryker MAKO robots
 - Zimmer ROSA robots
 - Medtronic spinal robot
- Overall, this has allowed Circle to perform approximately 3,000+ robotic assisted surgeries to date, reflecting continued growth in advanced surgical activity.

Complex Procedures and Clinical Achievements

SEHA & SSMC




- 33 Liver and 130 Kidney Transplants carried out in 2025
- Delivered world's first ITVISMAT™ Gene-Replacement Therapy for the treatment of Spinal Muscular Atrophy.
- Performed a groundbreaking minimally invasive tricuspid valve replacement in a 14-year-old at SKMC, highlighting the facility's advanced paediatric cardiac expertise
- SSMC completed Abu Dhabi's first Hypoglossal Nerve Implant, a surgical therapy that stimulates tongue movement to keep airways open. This milestone positions SSMC as a subspecialty centre for treating moderate-to-severe OSA patients intolerant to CPAP therapy.
- SSMC team performed the first Auditory Brainstem Implant (ABI) within the Abu Dhabi region. An ABI can provide sound to people with profound hearing loss who aren't candidates for cochlear implants (patient present with absent cochlear nerve. The treatment marks a major milestone in regional healthcare, offering advanced neuro-otological care locally and reducing the need for patients to seek treatment abroad.
- Rhabdomyosarcoma tumor embolization (buccal cavity) in a 14-month-old child.
- Middle meningeal artery embolization for chronic subdural hematomas at SSMC
- Successful removal of a 29 kg ovarian tumor.
- Reconstruction of complex head and neck defects using advanced microvascular techniques.
- Completed a rare dual liver-kidney transplant for a 10-year-old with a congenital condition, followed by a sibling kidney transplant, showcasing complex paediatric transplant expertise
- Performed a rare procedure performing laparoscopic subtotal pancreatectomy in a 4-month baby for Nesidioblastosis

Circle Health

- 100 Cytoreductive surgeries for Pseudomyxoma performed in 2025
- Complex Cases:
 - 100 Revision Joints
 - 40 Insertion of ICD
 - 19 TAVI (Transcatheter Aortic Valve Implantation)
 - 07 Repair of Tricuspid Valve
- Robotic Assisted Procedures:
 - 3,158 robotic assisted procedures performed in 2025
 - 700+ VELYS robotic surgeries performed in 2025
- 401 Complex spinal surgeries performed in 2025

Appendix

FY 2025 Segment Value & Contribution in %



Corporate Structure

Care

Hospital and Other Related Services UAE:

(“Hospitals”)

- Abu Dhabi Health Services Company (“SEHA”)
- SEHA Clinics (formerly “Ambulatory Healthcare Services”)
- Sheikh Shakhbout Medical City (“SSMC”)
- The Medical Office (“TMO”)
- National Rehabilitation Center (“NRC”)
- Tamouh Healthcare
- The Life Corner
- Dawak

International:

- Circle Health Group
- Hellenic Healthcare Group (financials consolidated from Q4 2025)
- Ardent Health Partners Inc (classified as a minority equity investment (21%))

Diagnostic Services

- PureLab

Procurement and Supply of Medical Related Products

- Rafed
- One Health

Technology Services and Others

- Pure CS
- Talent One

Cover

Insurance Services

- National Insurance Company (“Daman”)

About PureHealth

PureHealth (PureHealth Holding PJSC, listed on the Abu Dhabi Securities Exchange: PHH) is the largest healthcare provider in the United Arab Emirates and a leader in the healthcare sector across the MENA region. The Group operates a diverse portfolio that includes over 110 hospitals, over 13,000 licensed beds, insurance, and 143+ laboratories. With its headquarters in Abu Dhabi, PureHealth employs a global team of over 67,000 healthcare practitioners, administrators, and support staff. In 2025, PureHealth catered to around 3.4 million insured members and processed over 56 million insurance claims. As the region's only vertically integrated healthcare platform, PureHealth is committed to transforming healthcare delivery through continuous innovation, operational excellence, and sustainable practices to enhance the well-being of the communities it serves.

Institutional Investor Contact

PureHealth Investor Relations

ir@purehealth.ae

+971 2 2018200

+971 2 2018201

Corporate Headquarters Address

PureHealth Headquarters

Aldar Headquarters Building,

Al Rahah Street,

Abu Dhabi, UAE

Disclaimer

All information included in this document is for general use only and has not been independently verified, nor does it constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in the United Arab Emirates, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of PureHealth Holding PJSC.

PureHealth Holding PJSC does not warranty, express or implied, is made, and no reliance should be placed by any person or any legal entity for any purpose on the information and opinions contained in this document, or its fairness, accuracy, completeness or correctness.

This document may include statements that are, or may be deemed to be, "forward-looking statements" with respect to the Group's financial position, results of operations and business. Information on the Group's plans, intentions, expectations, assumptions, goals and beliefs are for general update only and do not constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in any jurisdiction, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of PureHealth Holding PJSC.